Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

Laviana Pharma Closes $15 Million Financing for China CRO/CMO Services

publication date: Jan 2, 2018

Laviana Pharma, a CRO/CMO with subsidiaries in Beijing and Tianjin, plus a business office in the US, closed a $15 million Series B funding led by Shenzhen Huayi Capital. Founded in 2005 by returnees, Laviana provides outsourced small molecule process and manufacturing services to pharmaceutical companies. In 2016, Laviana listed shares on China's NEEQ, an OTC exchange that lists shares without raising any capital for companies. More details....

Stock Symbol: (NEEQ: 838853)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.